BIOLASE, INC. (NASDAQ:BIOL) Files An 8-K Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition.
On March 5, 2019, BIOLASE, Inc. issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2018. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is hereby incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
The following exhibit is being furnished as part of this Current Report on Form 8-K:
BIOLASE, INC Exhibit
EX-99.1 2 biol-ex991_11.htm EX-99.1 biol-ex991_11.htm Exhibit 99.1 BIOLASE Reports 2018 Fourth Quarter and Full Year Results – Fourth Quarter U.S. Laser Revenue Increased 51% Year Over Year – – Fourth Quarter U.S. Consumables and Other Revenue Increased 13% Year Over Year – – 2018 Gross Margin Increased by nearly 1,…
To view the full exhibit click
About BIOLASE, INC. (NASDAQ:BIOL)
BIOLASE, Inc. (BIOLASE) is a medical device company that develops, manufactures, markets and sells laser systems in dentistry and medicine. The Company markets, sells, and distributes dental imaging equipment, including cone beam digital x-rays and computer-aided design (CAD)/computer-aided manufacturing (CAM) intra-oral scanners, in-office, chair-side milling machines and three-dimensional (3-D) printers. It offers two categories of laser system products: WaterLase (all-tissue) systems and Diode (soft tissue) systems. Its brand, WaterLase, uses a combination of water and laser energy to perform procedures performed using drills, scalpels, and other traditional dental instruments for cutting soft and hard tissue. It also offers its Diode laser systems to perform soft tissue, pain therapy, and cosmetic procedures, including teeth whitening. Its Waterlase and Diode systems use disposable laser tips of differing sizes and shapes depending on the procedures being performed.